Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products. It is primarily developing Northera (droxidopa), a therapeutic agent that is used for the treatment of symptomatic neurogenic orthostatic hypotension (Neurogenic OH) in patients with primary autonomic failure, dopamine-ß-hydroxylase, and deficiency and non-diabetic autonomic neuropathy. The company is also evaluating the potential therapeutic applications of droxidopa in reducing the frequency of falls in patients with Neurogenic OH associated with Parkinson’s disease, as well as other potentially norepinephrine-related conditions and diseases, including intradialytic hypotension, fibromyalgia, and adult attention deficit hyperactivity disorder. In addition, it engages in developing a portfolio of metabolically inert antifolates for the treatment of rheumatoid arthritis, and for the treatment of multiple other autoimmune disorders, including psoriasis, Crohn’s disease, uveitis, ankylosing spondylitis, inflammatory bowel disease, cancer, and other immunological disorders. Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina.

Key Statistics